When was Pencil Biosciences founded?

Pencil Biosciences was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Pencil Biosciences located?

Pencil Biosciences is headquartered in Alderley Edge, United Kingdom. It is registered at Alderley Edge (United Kingdom).

Who is the current CEO of Pencil Biosciences?

Amanda Smith of Pencil Biosciences.

Which legal entities is Pencil Biosciences associated with?

Pencil Biosciences is associated with Pencil Biosciences Limited.

How many employees does Pencil Biosciences have?

As of Sep 30, 2026, the latest employee count at Pencil Biosciences is 18.

Is Pencil Biosciences a funded company?

Pencil Biosciences is a funded company, having raised a total of $10.4M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 16, 2019.

How much is Pencil Biosciences worth?

The latest valuation of Pencil Biosciences is £***** as of Aug 16, 2023.

When was the latest funding round of Pencil Biosciences?

Pencil Biosciences' latest funding was a $***** Seed round on Aug 16, 2023, with participation from 8 investors.

Where does Pencil Biosciences rank among its competitors?

Pencil Biosciences ranks 28th amongst 130 active competitors, of which 59 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was eGenesis, which secured $14M in Aug, 2026.

Who are the top competitors of Pencil Biosciences?

Pencil Biosciences' top competitors include Beam Therapeutics, eGenesis and Mammoth. Among them, eGenesis secured the most recent funding round in August, 2026.

Pencil Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Pencil Biosciences is a seed company based in Alderley Edge (United Kingdom), founded in 2018 by Timothy Schulz Utermoehl. It operates as a Provider of gene-editing technology. Pencil Biosciences has raised $10.4M in funding from investors like Octopus Ventures, Syndicate Room and o2h ventures, with a current valuation of £*****. The company has 130 active competitors, including 59 funded and 13 that have exited. Its top competitors include companies like Beam Therapeutics, eGenesis and Mammoth.

Company Details

Pencil Biosciences is a provider of gene-editing technology. It is developing an innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases.

Website: www.pencilbiosciences.com/
Registered Address: Alderley Edge (United Kingdom)

Key Metrics

Founded Year

2018

Location

Alderley Edge, United Kingdom

Stage

Seed

Total Funding

$10.4M in 4 rounds

Latest Funding Round

Seed, Aug 16, 2023, $*****

Post Money Valuation

£***** as on Aug 16, 2023

Investors

Octopus Ventures & 17 more

Ranked

28^th among 130 active competitors

Employee Count

18 as on Sep 30, 2026

Similar Companies

Beam Therapeutics & 146 more

View Pencil Biosciences' full profile

Pencil Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Pencil Biosciences Limited CIN: 11660861 , United Kingdom, Active	Nov 04, 2018	-	10 (As on Aug 31, 2022)

Pencil Biosciences has raised a total funding of $10.4M over 4 rounds. Its first funding round was on Nov 16, 2019. Its latest funding round was a Seed round on Aug 16, 2023 for $*****. 8 investors participated in its latest round. Pencil Biosciences has 12 institutional investors and 6 angel investors.

Here is the list of recent funding rounds of Pencil Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 16, 2023	7060471	Seed	6246741	1225207	2288167	8298966
Feb 17, 2020	6703413	Seed	2889818	7732456	9466683	7994175
Dec 11, 2019	8112475	Seed	3551333	4941918	6231604	UK Innovation Science & Seed Fund & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Pencil Biosciences's funding rounds and investors

The founders of Pencil Biosciences is Timothy Schulz Utermoehl. Amanda Smith is the CEO of Pencil Biosciences.

Here are the details of Pencil Biosciences' key team members:

Timothy Schulz Utermoehl: Co-Founder of Pencil Biosciences and founder of 1 other company.
Amanda Smith: CEO of Pencil Biosciences.
Contact Info: 1 email address

View details of Pencil Biosciences's Founder profiles and Board Members

Pencil Biosciences' employee count trend

Pencil Biosciences has 18 employees as of Sep 26. Here is Pencil Biosciences's employee count trend over the years:

Employee count trend for Pencil Biosciences

Uncover Pencil Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pencil Biosciences include Beam Therapeutics, eGenesis and Mammoth. Here is the list of Top 10 competitors of Pencil Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	71/100
2nd	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$495M	Monashee Investment Management, Farallon Capital Management ... & 31 others	65/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
4th	Scribe Therapeutics 2018, Alameda (United States), Public	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 7 others	65/100
5th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
6th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
7th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	T. Rowe Price, Redmile Group & 10 others	63/100
8th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	T. Rowe Price, ADIA & 22 others	63/100
9th	Kytopen 2017, Cambridge (United States), Series B	Developer of gene delivery systems for cell therapy	$44.5M	Northpond Ventures, Horizons Ventures & 12 others	61/100
10th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	60/100
28th	Pencil Biosciences 2018, Alderley Edge (United Kingdom), Seed	Provider of gene-editing technology	$10.4M	Octopus Ventures, EMV Capital & 16 others	46/100